Overview

Effects of Blood Pressure Reduction on High Sensitivity C-Reactive Protein (hsCRP)

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The study compares the efficacy of an aggressive versus a moderate initial antihypertensive regimen to reduce blood pressure in patients with Stage 2 hypertension. Additionally, the study examines the effects of blood pressure reduction on the levels of high sensitivity hsCRP. Although the main goal is to determine the overall effect of blood pressure reduction on hsCRP levels, analysis will also evaluate whether an aggressive antihypertensive regimen is more effective than a moderate one in reducing hsCRP levels.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Valsartan